HLA-A2-restricted peptide epitopes of CD105 (endoglin) for cancer vaccination
The following invention is a new, peptide based vaccination against genetical stable tumor stroma-associated antigens. Because of significant upregulation of certain proteins (e.g. FAPα, CD105) tumor stroma cells are suitable targets for anti-tumor therapy. This technology employs these specific antigens in the vaccine design to avoid an immunologic attack on normal unaltered cells.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Security vulnerability in browser interface
… allows computer access via graphics card. Researchers at Graz University of Technology were successful with three different side-channel attacks on graphics cards via the WebGPU browser interface. The attacks…
A closer look at mechanochemistry
Ferdi Schüth and his team at the Max Planck Institut für Kohlenforschung in Mülheim/Germany have been studying the phenomena of mechanochemistry for several years. But what actually happens at the…
Severe Vulnerabilities Discovered in Software to Protect Internet Routing
A research team from the National Research Center for Applied Cybersecurity ATHENE led by Prof. Dr. Haya Schulmann has uncovered 18 vulnerabilities in crucial software components of Resource Public Key…
